Sarah Jordan

Sarah Jordan is a partner in Goodwin’s Antitrust and Competition practice. Dual qualified to practice in both England & Wales and Belgium, Sarah has a broad range of experience advising on European and UK competition law matters, including EU, UK, and international merger control and foreign investment matters, antitrust counselling, cartels, and compliance.

Sarah is recognized as a leading lawyer in The Legal 500 UK and Who’s Who Legal Global Elite.

Sarah’s experience includes work with sectors as diverse as pharmaceuticals, air transport, directory and internet services, basic manufacturing and construction materials, chemicals, brewing, digital storage products, financial services, and paper. Her representative experience includes advising:

• Roku in its pending $22bn sale to FOX
• Topaz Labs in its pending sale to Adobe
• Memo Therapeutics AG on its acquisition by Ipsen for over €700m
• Myricx Bio on its agreement to be acquired by Novartis for up to $1.5bn
• MaintainX in its sale to Autodesk for ~$3.6bn
• Avadel Pharmaceuticals in its $2.1bn acquisition by Alkermes plc
• Halda Therapeutics in its $3.05bn acquisition by Johnson & Johnson
• Blueprint Medicines in its acquisition by Sanofi for up to $9.5bn
• SpringWorks Therapeutics in its acquisition by Merck KGaA for up to $3.9bn
• Zealand Pharma A/S in its collaboration and license agreement with F. Hoffmann-La Roche AG worth up to $5.3bn
• 2seventy bio in its acquisition by Bristol Myers Squibb
• Silo AI in its acquisition by Advanced Micro Devices, Inc.
• Endomagnetics in its acquisition by Hologic, Inc.
• Deciphera Pharmaceuticals in its $2.4bn acquisition by ONO Pharmaceutical
• iRobot Corporation in its $1.7bn proposed acquisition by Amazon.com, Inc.
• Thoma Bravo and its portfolio company Flexera in the acquisition of IT asset management firm Snow Software
• A leading company in the fashion industry in multi-jurisdictional cartel investigation
• Renesas Electronics Corporation in its acquisition of Sequans Communications
• Tata Communications in its acquisition of Kaleyra
• Pulsic in its acquisition by Cadence
• ReViral in its $525m acquisition by Pfizer, Inc.
• TCR² Therapeutics in its acquisition by Adaptimmune Therapeutics
• Forma Therapeutics on its $1.1bn sale to Novo Nordisk
• Ritchie Bros. Auctioneers in its $7.3bn acquisition of IAA, Inc.
• Citrix Systems in its $16.5bn sale to Vista Equity Partners and Evergreen Coast Capital
• Biocon Biologics Ltd. in its $3.335bn agreement to acquire Viatris Inc.’s global biosimilars business
• Mimecast Limited in its $5.8bn acquisition by Permira
• GTCR and Corza Health, Inc., on the acquisition of TachoSil® Fibrin Sealant Patch from Takeda*
• A bidding consortium led by Advent, Cinven, and the RAG-Stiftung on the acquisition of the elevator division of thyssenkrupp AG*
• Avaya Holdings Corp. on a strategic partnership with RingCentral, Inc.*
• Advanced, a portfolio company of BC Partners and Vista Equity Partners, on its acquisition of legal technology business Tikit Limited from BT*
• Valeo Foods on its acquisition of Tangerine Confectionery*
• Accuride Corporation, a portfolio company of Crestview Partners, in connection with the acquisition of mefro wheels*
• Creat Group Corporation on its acquisition of Biotest AG*
• Vista Equity Partners in its $1.6 bn acquisition of Infoblox Inc.*
• Vista Equity Partners on the $1.65 bn acquisition of Cvent, Inc.*

*Denotes experience prior to joining Goodwin.

Prior to joining Goodwin, Sarah was most recently a partner at Kirkland & Ellis International LLP in London.

Sarah is a past chair of The Competition Section, Law Society of England and Wales. She is also a member of the American Bar Association, Antitrust Section.

Sarah was recognized for her work in The Legal 500 UK 2024 as a Leading Individual in EU and Competition law. She was also recognized in ‘Competition - Global Elite Thought Leader’ (2022-2023) by Who’s Who Legal, which described her as “very well known in the market” and “particularly good on deals.”

Sarah was identified as a ‘Rising Star’ (2014) by Law360.

• Co-Author, “UK and EU antitrust authorities target AI partnerships in expansion of merger control rules,” GCR Digital Markets Guide – Fifth Edition, September 2025
• Co-Author, “The General Court of the European Union Annuls a €1.5 Billion Fine Against Google AdSense,” Goodwin Insight, October 3, 2024
• Co-Author, “UK National Security and Investment Regime: Government Publishes Latest Annual Report,” Goodwin Alert, September 13, 2024
• Co-Author, “In a Landmark Judgment, Top European Court Curbs European Commission’s Ability to Review “Killer Acquisitions,” Goodwin Alert, September 6, 2024
• Co-Author, “European Commission's First-Ever Abuse of Dominance Probe for shelving of a Novel Pipeline Therapy,” Goodwin Client Alert, April 24, 2024
• Co-Author, “Antitrust & Competition Technology 2023 Year in Review,” Goodwin Insights, March 25, 2024
• Co-Author, “Antitrust & Competition Technology 2022 Year in Review,” Goodwin Insights, February 21, 2023
• Co-Author, “EU Antitrust vs. U.S. Companies,” Law360, February 4, 2016
• Speaker, “Antitrust: Implications for M&A and JVs,” GCR Live 6th Annual Antitrust Law Leaders Forum, Miami, February 2017
• Speaker, “Compliance Workshop,” IBC Legal, Advanced EU Competition Law Conference, Brussels, November 2016